Senator Tom Cotton (R-AR) is sounding the alarm on a disturbing double standard that has plagued American drug policy: while Chinese pharmaceutical companies get fast-tracked approval, American businesses are drowning in regulatory quicksand.
Speaking at a recent Breitbart News event, Cotton highlighted the glaring hypocrisy of a system that rolls out the red carpet for Communist China while strangling American innovation with bureaucratic chains.
"We shouldn't be greenlighting Chinese drugs while drowning American companies in red tape," Cotton declared, cutting straight to the heart of an issue that exemplifies everything wrong with the administrative state's priorities.
The China Problem Patriots Can't Ignore
This isn't just about business – it's about national security, folks. When we make it easier for Chinese companies to flood our market with pharmaceuticals than for American entrepreneurs to develop life-saving treatments, we're not just betraying our own workers. We're handing strategic control over our healthcare supply chain to our greatest geopolitical rival.
Cotton's warning comes at a crucial time as President Trump's second-term agenda focuses laser-like on dismantling the regulatory apparatus that has handicapped American competitiveness for decades. The Trump-Vance administration's commitment to "America First" trade policies directly addresses this regulatory insanity.
"The threats of China are real and immediate," Cotton emphasized, "and our drug approval process should reflect American interests, not Chinese convenience."
Under the previous Biden regime, federal agencies seemed more interested in appeasing global interests than protecting American innovation. The result? A pharmaceutical landscape where Communist China gained unfair advantages while American companies faced endless bureaucratic obstacles.
DOGE and Deregulation: The Path Forward
Fortunately, with Elon Musk leading the Department of Government Efficiency (DOGE), these kinds of regulatory double standards are exactly what's being targeted for elimination. The Trump administration's deregulation agenda isn't just about cutting red tape – it's about ensuring American companies can compete on a level playing field.
Cotton's message is clear: America should never make it easier for foreign adversaries to access our markets than for our own citizens to build businesses. It's time to put America First – starting with the drugs that keep Americans healthy.